Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune Inc (ALT) is a clinical-stage biopharmaceutical company pioneering peptide-based therapeutics for obesity, metabolic disorders, and liver diseases. This page serves as the definitive source for verified news and press releases directly from the company and trusted financial publications.
Investors and researchers will find timely updates on clinical trial progress, including developments for pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate. Track regulatory milestones, partnership announcements, and strategic initiatives that shape Altimmune’s research pipeline.
Our curated news feed includes earnings reports, scientific presentations, and manufacturing updates, providing a holistic view of the company’s trajectory. All content is rigorously vetted to ensure alignment with financial reporting standards and clinical accuracy.
Bookmark this page for efficient access to Altimmune’s latest material events. Check regularly for updates on pivotal studies in metabolic-associated steatohepatitis (MASH) and obesity therapeutics, ensuring you stay informed on developments impacting this innovative biopharma leader.
Altimmune, Inc. (Nasdaq: ALT) has successfully completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic targeting chronic hepatitis B (CHB). This trial involves approximately 80 subjects across 26 sites in North America, Europe, and Southeast Asia. The primary endpoint is a significant reduction in hepatitis B surface antigen (HBsAg). The data readout is anticipated in Q1 2024. HepTcell, which combines nine synthetic peptides with an adjuvant, aims to provoke immune responses against HBV. Given the disease’s global impact, affecting around 296 million people and resulting in over 800,000 deaths annually, this trial may pave the way toward a functional cure for CHB. Additionally, Altimmune is set to initiate a Phase 2b trial for non-alcoholic steatohepatitis (NASH) in mid-2023, with key data from an obesity trial expected in late 2023.
Altimmune, Inc. (Nasdaq: ALT) has appointed Catherine Angell Sohn, Pharm.D., to its Board of Directors, effective March 27, 2023. Her extensive experience in pharmaceutical product development and commercialization is expected to benefit Altimmune’s mission to create next-generation peptide therapeutics for obesity and liver diseases. Currently an independent director at Jazz Pharmaceuticals and Axcella Health, Dr. Sohn previously held strategic roles at GlaxoSmithKline, driving significant acquisitions and launches. She aims to support Altimmune’s clinical pipeline, which includes pemvidutide for obesity and HepTcell™ for chronic hepatitis B.
Altimmune announced the MOMENTUM Phase 2 obesity trial results, reporting a mean weight loss of 10.7% at the 2.4 mg dose after 24 weeks, with 50% of subjects achieving 10% or more weight loss. Significantly, subjects under 115 kg achieved a mean weight loss of 11.9%. Improvements in waist circumference, serum lipids, and blood pressure were also noted without significant heart rate changes. The Phase 1b safety trial for Type 2 diabetes showed 7.7% weight loss at the same dose. Adverse events were similar to earlier trials, primarily gastrointestinal.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
